Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria
Journal of Allergy and Clinical Immunology · 2026-11 · 158 (5) · 1235-1237
DOI: 10.1016/j.jaci.2026.08.002 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-11. Verfasst von Matthew P Giannetti. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: mg…. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: mgiannetti@bwh.harvard.edu.
Zitieren
APA
Giannetti, M. P. (2026). Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 158(5), 1235-1237. https://doi.org/10.1016/j.jaci.2026.08.002
Vancouver
Giannetti MP. Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology. 2026;158(5):1235-1237. doi:10.1016/j.jaci.2026.08.002
BibTeX
@article{Giannetti2026,
author = {Giannetti, Matthew P},
title = {Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {158},
number = {5},
pages = {1235--1237},
doi = {10.1016/j.jaci.2026.08.002}
}
EUVIMED